APEIRON shareholders approve new group structure geared towards enabling innovation and growth
Shareholders in APEIRON Biologics AG will be granted shares in invIOs Holding AG pro rata to their current shareholdings in APEIRON Biologics AG.
- Shareholders in APEIRON Biologics AG will be granted shares in invIOs Holding AG pro rata to their current shareholdings in APEIRON Biologics AG.
- AResT will drive the development of APN01, currently being developed for the treatment of COVID-19 and other respiratory and pulmonary indications.
- The new group structure approved by the AGM is an important step forward in enabling our innovation and growth, and we are grateful to our shareholders for their ongoing support.
- APEIRON Biologics is a privately held biotech company based in Vienna, Austria.